|
 The company, whose shares were up 41 percent in extended trading,
said it expects to resubmit a marketing application for the drug to
the U.S. FDA in mid-2015.
The company had filed for marketing application for Sustol twice but
the FDA had sought additional data.
The drug, Sustol, in combination with two other drugs, was compared
with a standard-of-care three-drug regimen.
The percentage of patients who achieved the main goal of complete
response was significantly higher in the Sustol group.
Heron shares had closed at $12.35 on the Nasdaq on Thursday.
(Reporting by Shailesh Kuber; Editing by Don Sebastian)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
|
